A randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of Nexvax2 in patients with celiac disease.
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs HLA DQ2 peptide vaccine (Primary)
- Indications Coeliac disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors ImmusanT
- 31 Oct 2017 According to an ImmusanT media release, data were presented at the United European Gastrointestinal (UEG) Week, Nov 2017.
- 12 Oct 2017 According to an ImmusanT media release, data from this trial will be presented at the United European Gastrointestinal (UEG) Week, Nov 2017.
- 12 May 2017 Results from this and other trial (see profile 215705) published in an ImmusanT Media Release
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History